Valued at a market cap of $28 billion, San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally.
Companies with a market cap of $10 billion or more are typically referred to as “big-cap stocks.” DXCM fits squarely into that category, with its market cap exceeding this threshold and reflecting its substantial size and influence in the medical devices industry.
